December 6, 2008AstraZeneca's new lung drug may face US delay - KIDK AstraZeneca's new lung drug may face US delay - KIDK
LONDON (AP) - AstraZeneca PLC could have to delay the rollout of its new infant lung drug in the United States because the Food and Drug Administration has asked for more information about the medicine before allowing it on the market. AstraZeneca Source: www.kidk.com GlaxoSmithKline: Study Shows Promacta Aids Blood Condition - Beurs.nl GlaxoSmithKline PLC (GSK) said Saturday that a recent long-term study of its new drug to treat a blood condition showed positive results. The Food and Drug Administration last month granted accelerated approval to the drug, Promacta. The FDA's Source: www.beurs.nl FDA: Risks of new asthma drugs vary - PhysOrg But a less widely used medication, Serevent, had a significantly higher rate of complications when compared to older treatments, the Food and Drug Administration said. Both drugs are made by the same company, GlaxoSmithKline. FDA safety reviewers are Source: www.physorg.com Risks for new asthma drugs vary, FDA warns - TriVallyCentral WASHINGTON - The blockbuster asthma drug Advair does not appear to have an increased risk of serious respiratory complications seen with similar new medicines, federal health officials said Friday. But a less widely used medication, Serevent, had a Source: www.zwire.com WHO limits melamine in food, says traces seem safe - Philadelphia Inquirer GENEVA - The World Health Organization said Friday that tiny traces of the chemical melamine are not harmful in most foods, but it joined the U.S. and EU in setting a strict limit that regulators should impose before pulling products off the shelf Source: www.philly.com # posted by Network @ 1:00 PM
 |
Subscribe to Posts [Atom]